Paediatric primary cutaneous marginal zone B‐cell lymphoma: does it differ from its adult counterpart?. (1st April 2017)

• Record Type: Journal Article
• Authors: Amitay‐Laish, I.; Tavallaee, M.; Kim, J.; Hoppe, R.T.; Million, L.; Feinmesser, M.; Fenig, E.; Wolfe, M.E.L.; Hodak, E.; Kim, Y.H.
• Is Part Of: British journal of dermatology. Volume 176:Number 4(2017)
• Page Start: 1010
• Page End: 1020
• Publication Date: 2017-04-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.14932
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Primary cutaneous marginal zone B‐cell lymphoma (PCMZL) has rarely been reported in patients younger than 20 years. Objectives: To report our experience with PCMZL in the paediatric/adolescent age group. Methods: Medical records of patients diagnosed with PCMZL before age 20 years and managed at two cutaneous lymphoma clinics in the U.S.A. and Israel from 1992 to 2015 were reviewed. Results: The study group included 11 patients (six girls; median age 16 years, range 6–19·5); 10 had generalized/multifocal (T3) and one had regional/localized (T2) disease. Lesions were located on the limbs in all patients and the trunk in six; two had facial lesions. Staging in all but one was based on whole‐body computed tomography or positron emission tomography. Initial management in most patients included nonradiation modalities: one patient with localized disease received intralesional steroids; six patients with multifocal disease received the following: topical/intralesional steroids ( n = 3); excision ( n = 2); 'watch and wait' ( n = 1). No extracutaneous progression was noted during a median follow‐up of 5·5 years (mean 7·5, range 0·5–14). At present, five patients are in complete remission. Conclusions: Based on our data (largest series in the literature with the longest follow‐up), the clinicopathological presentation and course of PCMZL in the paediatric/adolescent age group are similar to those in adults. Given the indolent course and the long life expectancy of these young patients, the cumulative risk of imaging studies and the age‐related potential toxicity of treatment, especially radiation, should be taken into consideration.